GHRH vs. GHRP: The Two Receptor Classes Behind Growth-Hormone Peptide Research

“Growth hormone peptide” is often used as if it describes one mechanism. In research literature, it actually covers two structurally and functionally distinct receptor classes — and mixing them up leads to confused study design.

Class One: GHRH Analogs

GHRH (growth hormone-releasing hormone) analogs, like Tesamorelin and CJC-1295, work by binding to GHRH receptors — mimicking the body’s natural release-triggering hormone. Research on this class typically examines dose-dependent receptor activation and binding duration.

Class Two: GHRPs / Secretagogues

GHRPs (growth hormone-releasing peptides) and secretagogues, like Ipamorelin, work through an entirely different receptor — the ghrelin receptor — and are studied for their secretagogue activity rather than direct GHRH-pathway mimicry.

Why the Distinction Changes Research Design

Because these two classes act on different receptors, combination research designs often pair one compound from each class specifically to study whether dual-pathway activation produces different outcomes than either pathway alone — a comparison that only makes sense once you understand they’re not interchangeable.

Reading Literature More Carefully

When reviewing published research, checking which receptor class a compound belongs to — rather than lumping everything under “GH peptides” — makes it much easier to understand why certain studies pair specific compounds together.

Sourcing for Research

We carry GHRH-class Tesamorelin 10mg and the combination CJC-1295 No DAC + IPA 10mg, which pairs a GHRH analog with a secretagogue in one vial.

Important: For laboratory research use only. Not for human or veterinary use.